首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1858825

生物偶联市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

Bioconjugation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年10月15日 | 出版商:

Global Market Insights Inc. | 英文 188 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2024 年全球生物偶联市场价值为 56 亿美元，预计到 2034 年将以 14.4% 的复合年增长率增长至 206 亿美元。

这一上升趋势与慢性病盛行率的上升以及对生物製剂和新一代疗法的需求不断增长密切相关。随着医疗保健系统和製药业将重心转向个人化治疗和精准医疗，对生物偶联工具和服务的需求持续增长。生物偶联透过将生物分子与药物或合成材料进行化学连接，在标靶治疗、诊断和研究创新方面发挥至关重要的作用。这些连接后的分子具有更高的性能、更精准的治疗效果和更大的治疗潜力。不断扩充的先进疗法研发管线和生物技术研究投入的增加，正显着推动市场对该技术的接受度。企业正越来越多地将这些技术整合到药物开发流程中，进一步推进其在疾病检测、治疗和生物标记追踪方面的应用。市场领导者的强大影响力、先进生物偶联试剂盒的普及以及对开发稳定且特异性生物分子连接的重视，共同促进了该领域的强劲增长。随着创新加速，该行业涌现出更多精简和高效的解决方案，从而促进了其在生物技术、製药和诊断领域的更广泛应用。

市场范围
起始年份	2024
预测年份	2025-2034
起始值	56亿美元
预测值	206亿美元
复合年增长率	14.4%

预计2025年至2034年间，服务领域的复合年增长率将达到15.3%。这一成长主要得益于製药和生物技术公司外包业务的激增，这些公司正转向合约研究和生产组织（CRMO）来管理复杂的生物偶联任务。这些合作关係有助于企业最大限度地降低营运成本，加快研发週期，并更快地将抗体药物偶联物和精准疗法等标靶治疗推向市场。因此，全球药物研发管线对生物偶联服务的需求日益增长。

2024年，抗体市场规模达23亿美元。抗体因其卓越的靶向能力，在生物偶联技术中发挥至关重要的作用。它们在药物偶联物中的广泛应用源于其识别并结合特定疾病标记的能力，从而实现更精准的治疗药物递送，同时减少对健康组织的损伤。除了治疗应用外，抗体在诊断和成像平台中也扮演着不可或缺的角色，因为在这些平台中，精准的生物标记检测至关重要。

预计到2024年，美国生物偶联市场规模将达22亿美元。美国强大的生物技术企业基础、充足的科学研究经费以及有利的监管环境，为其在该领域的领先地位提供了有力支撑。此外，美国还拥有大量创新生物偶联疗法在研产品线和正在进行的临床试验。尖端技术的普及和世界级研究机构的存在，不断拓展生物偶联技术的应用边界。

推动全球生物偶联市场成长与创新的关键企业包括：赛多利斯（Sartorius）、药明生物（WuXi Biologics）、安捷伦科技（Agilent Technologies）、查尔斯河实验室（Charles River Laboratories）、赛默飞世尔科技（Thermo Fisher Scientific）、西根（SeagenativeVkgenative Biolabs、BD、金斯瑞生物科技（GenScript Biotech Corporation）、丹纳赫公司（Danaher Corporation）、伯乐生物（Bio-Rad Laboratories）、Abzena、龙沙集团（Lonza Group）、Piramal Pharma Limited、基因泰克（罗氏集团）（Genentech (Roche Group)）和Catalent。为了保持竞争优势，生物偶联市场的企业正致力于透过积极的研发投入和持续的技术创新来增强其产品线。一些公司正透过与製药和生物技术公司建立策略联盟来扩展其服务能力，从而提供客製化解决方案。许多企业也在扩大生产规模并加强全球供应链，以满足对可偶联生物分子和试剂盒日益增长的需求。主要企业正透过引入先进的偶联化学技术来提高药物的稳定性和精确度，从而强调产品组合的多元化。

产业生态系分析
产业影响因素
- 成长驱动因素
  - 慢性病盛行率上升
  - 标靶治疗的进展
  - 生物偶联物的监管审批
  - 诊断领域应用范围的扩大
- 产业陷阱与挑战
  - 生物偶联过程的复杂性
  - 高昂的生产和开发成本
- 市场机会
  - 开发个人化和精准基因疗法
  - 随着医疗基础设施的不断发展，新兴市场将迎来扩张。
成长潜力分析
监管环境
- 北美洲
  - 我们
  - 加拿大
- 欧洲
- 亚太地区
- 拉丁美洲
- 中东和非洲
技术格局
- 当前趋势
- 新兴技术
未来市场趋势
波特的分析
PESTEL 分析

第四章：竞争格局

介绍
公司市占率分析
- 全球的
- 北美洲
- 欧洲
- 亚太地区
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
关键进展
- 併购
- 伙伴关係与合作
- 新产品发布
- 扩张计划

第五章：市场估算与预测：依组件划分，2021-2034年

主要趋势
产品
- 按类型
  - 消耗品
    - 试剂和试剂盒
    - 标籤
    - 其他消耗品
  - 仪器
    - 色谱系统
    - 光谱仪
    - 质谱仪
    - 流式细胞仪
    - 电泳设备
    - 过滤系统
    - 搅拌器和摇酒器
    - 孵化器
    - 其他乐器
- 按最终用途
  - 製药和生物技术公司
  - 合约研究组织 (CRO) 和合约生产组织 (CMO)
  - 医院、诊所、诊断实验室
  - 学术和研究机构
服务
- 按类型
  - 客製化合成和偶联服务
  - 分析和表征服务
  - 规模化和製造服务
  - 其他服务
- 按最终用途
  - 製药和生物技术公司
  - 医院、诊所、诊断实验室
  - 学术和研究机构

第六章：市场估算与预测：依生物分子类型划分，2021-2034年

主要趋势
抗体
蛋白质
胜肽
寡核苷酸
其他生物分子

第七章：市场估计与预测：依技术划分，2021-2034年

主要趋势
化学偶联
酶介导的结合
点击化学
光反应交联
其他技术

第八章：市场估算与预测：依应用领域划分，2021-2034年

主要趋势
疗法
- 抗体-药物偶联物
- 蛋白质-药物偶联物
- 胜肽-药物偶联物
- 其他治疗应用
研究与开发
诊断
其他应用

第九章：市场估计与预测：依地区划分，2021-2034年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋

第十章：公司简介

Abzena
AbbVie
Agilent Technologies
BD
Bio-Rad Laboratories
Catalent
Charles River Laboratories
Creative Biolabs
Danaher Corporation
GenScript Biotech Corporation
Genentech (Roche Group)
Lonza Group
Merck KGaA
Piramal Pharma Limited
Sartorius
Seagen
Thermo Fisher Scientific
WuXi Biologics

简介目录

Product Code: 14912

The Global Bioconjugation Market was valued at USD 5.6 billion in 2024 and is estimated to grow at a CAGR of 14.4% to reach USD 20.6 billion by 2034.

The upward trend is closely linked to the rising prevalence of chronic illnesses and the increasing demand for biologics and next-generation therapies. As healthcare systems and pharmaceutical industries shift focus toward personalized treatments and precision medicine, the need for bioconjugation tools and services continues to expand. Bioconjugation plays a critical role in enabling the development of targeted therapeutics, diagnostics, and research innovations by chemically linking biomolecules to drugs or synthetic materials. These linked molecules offer enhanced performance, precision, and therapeutic potential. The expanding pipeline of advanced therapeutics and the growing investment in biotechnology research are significantly boosting market adoption. Companies are increasingly integrating these technologies into drug development workflows, further advancing applications in disease detection, treatment, and biomarker tracking. The strong presence of market leaders, availability of advanced bioconjugation kits, and emphasis on developing stable and specific biomolecule linkages all contribute to the robust growth of this sector. As innovation accelerates, the industry is seeing more streamlined and efficient solutions, facilitating broader use across biotech, pharma, and diagnostics.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$5.6 Billion
Forecast Value	$20.6 Billion
CAGR	14.4%

The services segment is expected to grow at a CAGR of 15.3% during 2025-2034. This growth is being fueled by a surge in outsourcing from pharmaceutical and biotech firms, which are turning to contract research and manufacturing organizations to manage complex bioconjugation tasks. These partnerships help companies minimize operational expenses, speed up development cycles, and bring targeted treatments like antibody-drug conjugates and precision therapies to market faster. As a result, bioconjugation services are seeing increased demand across global drug development pipelines.

In 2024, the antibodies segment generated USD 2.3 billion. Antibodies play a vital role in bioconjugate technologies due to their exceptional targeting capabilities. Their widespread use in drug conjugates stems from their ability to identify and bind to specific disease markers, allowing for more focused delivery of therapeutic agents while reducing harm to healthy tissue. Beyond therapeutics, antibodies are also integral to diagnostic and imaging platforms where accurate biomarker detection is essential.

U.S. Bioconjugation Market reached USD 2.2 billion in 2024. This leadership position is supported by the country's strong base of biotech firms, well-funded research environment, and favorable regulatory framework. The U.S. also benefits from a pipeline filled with innovative bioconjugated therapies and a wealth of ongoing clinical trials. Access to cutting-edge technologies and the presence of world-renowned research institutions continue to push the boundaries of what bioconjugation can achieve.

Key companies driving growth and innovation in the Global Bioconjugation Market include Sartorius, WuXi Biologics, Agilent Technologies, Charles River Laboratories, Thermo Fisher Scientific, Seagen, Merck KGaA, AbbVie, Creative Biolabs, BD, GenScript Biotech Corporation, Danaher Corporation, Bio-Rad Laboratories, Abzena, Lonza Group, Piramal Pharma Limited, Genentech (Roche Group), and Catalent. To maintain a competitive edge, companies in the Bioconjugation Market are focusing on enhancing their product pipelines through aggressive R&D investment and continuous technology innovation. Several firms are expanding their service capabilities by entering strategic alliances with pharmaceutical and biotechnology companies to offer custom solutions. Many players are also scaling up manufacturing facilities and strengthening global supply chains to support increasing demand for conjugation-ready biomolecules and kits. Key businesses are emphasizing portfolio diversification by introducing advanced conjugation chemistries that improve drug stability and precision.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Data mining sources
- 1.3.1 Global
- 1.3.2 Regional/Country
1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
1.5 Primary research and validation
- 1.5.1 Primary sources
1.6 Forecast model
1.7 Research assumptions and limitations

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis
2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Component trends
- 2.2.3 Biomolecule type trends
- 2.2.4 Technique trends
- 2.2.5 Application trends
2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of chronic diseases
  - 3.2.1.2 Advancements in targeted therapies
  - 3.2.1.3 Regulatory approvals for bioconjugates
  - 3.2.1.4 Expanding applications in diagnostics
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Complexity of bioconjugation processes
  - 3.2.2.2 High production and development costs
- 3.2.3 Market opportunities
  - 3.2.3.1 Development of personalized and precision gene therapies
  - 3.2.3.2 Expansion in emerging markets with growing healthcare infrastructure
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 North America
  - 3.4.1.1 U.S.
  - 3.4.1.2 Canada
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.4.4 Latin America
- 3.4.5 Middle East and Africa
3.5 Technology landscape
- 3.5.1 Current trends
- 3.5.2 Emerging technologies
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company market share analysis
- 4.2.1 Global
- 4.2.2 North America
- 4.2.3 Europe
- 4.2.4 Asia Pacific
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
- 4.6.1 Merger and acquisition
- 4.6.2 Partnership and collaboration
- 4.6.3 New product launches
- 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Component, 2021 - 2034 ($ Mn)

5.1 Key trends
5.2 Product
- 5.2.1 By type
  - 5.2.1.1 Consumables
    - 5.2.1.1.1 Reagents and kits
    - 5.2.1.1.2 Labels
    - 5.2.1.1.3 Other consumables
  - 5.2.1.2 Instruments
    - 5.2.1.2.1 Chromatography systems
    - 5.2.1.2.2 Spectroscopy instruments
    - 5.2.1.2.3 Mass spectrometers
    - 5.2.1.2.4 Flow cytometers
    - 5.2.1.2.5 Electrophoresis equipment
    - 5.2.1.2.6 Filtration systems
    - 5.2.1.2.7 Mixers and shakers
    - 5.2.1.2.8 Incubators
    - 5.2.1.2.9 Other instruments
- 5.2.2 By end use
  - 5.2.2.1 Pharmaceutical and biotechnology companies
  - 5.2.2.2 CROs and CMOs
  - 5.2.2.3 Hospitals, clinics, diagnostic laboratories
  - 5.2.2.4 Academic and research institutes
5.3 Services
- 5.3.1 By type
  - 5.3.1.1 Custom synthesis and conjugation services
  - 5.3.1.2 Analytical and characterization services
  - 5.3.1.3 Scale-up and manufacturing services
  - 5.3.1.4 Other services
- 5.3.2 By end use
  - 5.3.2.1 Pharmaceutical and biotechnology companies
  - 5.3.2.2 Hospitals, clinics, diagnostic laboratories
  - 5.3.2.3 Academic and research institutes

Chapter 6 Market Estimates and Forecast, By Biomolecule Type, 2021 - 2034 ($ Mn)

6.1 Key trends
6.2 Antibodies
6.3 Proteins
6.4 Peptides
6.5 Oligonucleotides
6.6 Other biomolecules

Chapter 7 Market Estimates and Forecast, By Technique, 2021 - 2034 ($ Mn)

7.1 Key trends
7.2 Chemical conjugation
7.3 Enzyme-mediated conjugation
7.4 Click chemistry
7.5 Photoreactive crosslinking
7.6 Other techniques

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

8.1 Key trends
8.2 Therapeutics
- 8.2.1 Antibody-drug conjugates
- 8.2.2 Protein-drug conjugates
- 8.2.3 Peptide-drug conjugates
- 8.2.4 Other therapeutic applications
8.3 Research and development
8.4 Diagnostics
8.5 Other applications

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 India
- 9.4.3 Japan
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE